BerGenBio ASA (BGBIO.OL)
NOK 1.67
(-2.0%)
NOK 1.67
(-2.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -191.8 Million NOK | 36.99% |
| 2022 | -300.91 Million NOK | 2.3% |
| 2021 | -307.99 Million NOK | -20.18% |
| 2020 | -260.92 Million NOK | -29.18% |
| 2019 | -198.38 Million NOK | -3.6% |
| 2018 | -191.54 Million NOK | -5.23% |
| 2017 | -183.51 Million NOK | -40.46% |
| 2016 | -131.36 Million NOK | -80.78% |
| 2015 | -72.74 Million NOK | -27.21% |
| 2014 | -57.5 Million NOK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -40.76 Million NOK | 30.29% |
| 2024 Q2 | -51.76 Million NOK | -40.53% |
| 2023 Q3 | -23.9 Million NOK | 47.75% |
| 2023 Q2 | -45.74 Million NOK | 33.99% |
| 2023 FY | - NOK | 36.99% |
| 2023 Q1 | -69.3 Million NOK | 18.71% |
| 2023 Q4 | -50.64 Million NOK | -111.87% |
| 2022 Q1 | -77.84 Million NOK | -5.45% |
| 2022 FY | - NOK | 2.3% |
| 2022 Q4 | -85.25 Million NOK | -52.59% |
| 2022 Q3 | -55.86 Million NOK | 31.83% |
| 2022 Q2 | -81.95 Million NOK | -5.28% |
| 2021 Q2 | -87.4 Million NOK | -11.03% |
| 2021 Q3 | -68.05 Million NOK | 22.13% |
| 2021 Q4 | -73.82 Million NOK | -8.48% |
| 2021 Q1 | -78.71 Million NOK | 6.4% |
| 2021 FY | - NOK | -20.18% |
| 2020 Q3 | -63.64 Million NOK | -4.33% |
| 2020 Q4 | -84.1 Million NOK | -32.15% |
| 2020 FY | - NOK | -29.18% |
| 2020 Q1 | -47.53 Million NOK | 22.26% |
| 2020 Q2 | -60.99 Million NOK | -28.32% |
| 2019 Q3 | -43.11 Million NOK | 14.21% |
| 2019 FY | - NOK | -3.6% |
| 2019 Q4 | -61.14 Million NOK | -41.82% |
| 2019 Q2 | -50.26 Million NOK | -14.59% |
| 2019 Q1 | -43.86 Million NOK | 15.12% |
| 2018 Q3 | -37.08 Million NOK | 24.4% |
| 2018 Q4 | -51.67 Million NOK | -39.35% |
| 2018 Q2 | -49.05 Million NOK | 8.62% |
| 2018 FY | - NOK | -5.23% |
| 2018 Q1 | -53.68 Million NOK | -9.12% |
| 2017 Q2 | -33.25 Million NOK | 48.54% |
| 2017 Q1 | -64.62 Million NOK | -127.45% |
| 2017 FY | - NOK | -40.46% |
| 2017 Q3 | -34.91 Million NOK | -5.0% |
| 2017 Q4 | -49.19 Million NOK | -40.91% |
| 2016 FY | - NOK | -80.78% |
| 2016 Q3 | -15.17 Million NOK | 76.96% |
| 2016 Q2 | -65.88 Million NOK | 0.0% |
| 2016 Q4 | -28.41 Million NOK | -87.2% |
| 2015 FY | - NOK | -27.21% |
| 2014 FY | - NOK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Arctic Bioscience AS | -37.78 Million NOK | -407.615% |
| Aqua Bio Technology ASA | -16.56 Million NOK | -1057.692% |
| ArcticZymes Technologies ASA | 31.64 Million NOK | 706.118% |
| Hofseth BioCare ASA | -70.6 Million NOK | -171.664% |
| PCI Biotech Holding ASA | -22.22 Million NOK | -763.109% |
| Thor Medical ASA | -6.82 Million NOK | -2708.61% |
| Ultimovacs ASA | -214.85 Million NOK | 10.728% |